In this issue of the Journal, Morton and colleagues1 report the final analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-I), a landmark prospective, randomized clinical trial that caps a 35-year effort to resolve the controversy surrounding the survival benefit of surgical excision of regional lymph nodes as a component of the initial treatment of patients with primary melanoma. Spanning two decades, the MSLT-I also shows the importance of the sentinel-node biopsy for staging and prognostic assessment of melanomas with a thickness of 1.20 mm or more. In the cohort of node-positive patients with intermediate-thickness primary melanomas (defined in this study . . .
No takes yet. Share an insight, caveat, or question.
Balch et al. (2014) studied this question.